ABVX|Abivax SA|Price:117.670|Chg%:6.96

More Details of Abivax SA Company

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Abivax SA Info



Ticker SymbolABVX

Company nameAbivax SA

IPO dateJun 26, 2015

CEOde Garidel (Marc)

Number of employees- -

Security typeDepository Receipt

Fiscal year-end- -

Address7-11 Boulevard Haussmann

CityPARIS

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryFrance

Postal code75009

Phone33153830963

Websitehttps://www.abivax.com/

Ticker SymbolABVX

IPO dateJun 26, 2015

CEOde Garidel (Marc)

Company Executives of Abivax SA



Name

Name/Position

Position

Shareholding

Change

Mr. Pierre Courteille

Chief Business Officer

--

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

--

Mr. Didier Bruno Blondel

Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors

--

Ms. Corinna Zur Bonsen-Thomas

Independent Director

--

Mr. Kinam Hong

Director, Representative of Sofinnova Partners

--

Mr. Jerome Denis, Ph.D.

Executive Vice President - Process Development & Manufacturing

--

Mr. Marc de Garidel

Chief Executive Officer

--

Ms. Ida Hatoum

Chief People Officer, Chief Compliance Officer

--

Dr. June H. Lee, M.D.

Independent Director

--

Mr. Troy A. Ignelzi

Independent Director

--

Name

Name/Position

Position

Shareholding

Change

Mr. Pierre Courteille

Chief Business Officer

--

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

--

Mr. Didier Bruno Blondel

Chief Financial Officer, Executive Vice President, Non-Member Secretary of the Board of Directors

--

Ms. Corinna Zur Bonsen-Thomas

Independent Director

--

Mr. Kinam Hong

Director, Representative of Sofinnova Partners

--

Mr. Jerome Denis, Ph.D.

Executive Vice President - Process Development & Manufacturing

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Mon, Jan 19

Shareholders

Shareholder Types

Shareholders

Proportion

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.01%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

Other

73.39%

Shareholders

Proportion

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.01%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

Other

73.39%

Shareholder Types

Shareholders

Proportion

Hedge Fund

33.85%

Investment Advisor

23.62%

Investment Advisor/Hedge Fund

8.93%

Research Firm

2.98%

Venture Capital

2.18%

Private Equity

1.77%

Pension Fund

1.00%

Bank and Trust

0.02%

Other

25.66%

Institutional Shareholding



Updated: Mon, Dec 8

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

216

53.64M

52.23%

+104.02K

2025Q3

210

53.54M

52.22%

+19.70M

2025Q2

81

30.74M

57.27%

-1.09M

2025Q1

75

31.82M

50.24%

-38.10K

2024Q4

68

29.91M

44.59%

+2.48M

2024Q3

54

27.43M

45.93%

-700.83K

2024Q2

51

33.52M

46.25%

-227.21K

2024Q1

46

28.78M

34.33%

+7.18M

2023Q4

33

27.04M

1.75%

+20.54M

2023Q3

1

5.40M

0.00%

--

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

TCG Crossover Management, LLC

7.11M

9.67%

+1.05M

+17.42%

Sep 30, 2025

UBS Financial Services, Inc.

4.46M

6.06%

+4.29M

+2560.74%

Sep 30, 2025

Darwin Global Management Ltd

3.16M

4.3%

+3.16M

--

Sep 30, 2025

Point72 Asset Management, L.P.

2.93M

3.98%

+2.76M

+1642.45%

Sep 30, 2025

Cormorant Asset Management, LP

1.95M

2.65%

-180.00K

-8.45%

Sep 30, 2025

Paradigm BioCapital Advisors LP

1.56M

2.13%

+1.56M

--

Sep 30, 2025

Caligan Partners, LP

1.45M

1.97%

-222.48K

-13.29%

Sep 30, 2025

Fidelity Management & Research Company LLC

1.43M

1.94%

+417.90K

+41.26%

Sep 30, 2025

Fred Alger Management, LLC

1.23M

1.67%

+40.31K

+3.38%

Dec 31, 2025

Adar1 Capital Management LLC

1.35M

1.84%

-1.72M

-56.02%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

Simplify Health Care ETF

2.86%

Harbor Health Care ETF

0.7%

Fidelity Nasdaq Composite Index ETF

0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

0%

Innovator IBD Breakout Opportunities ETF

0%

Simplify Health Care ETF

Proportion2.86%

Harbor Health Care ETF

Proportion0.7%

Fidelity Nasdaq Composite Index ETF

Proportion0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

Proportion0%

Innovator IBD Breakout Opportunities ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data